The patient incidence of adverse events in the safety analysis set ( all patients who received at least one dose of study drug ) did not differ between the denosumab group ( 1366 events , 80 % ) and the placebo group ( 1334 events , 79 % ) , nor did the numbers of serious adverse events ( 521 vs 511 [ 30 % in each group ] ) .